Abingworth Management, of London, appointed Tim Haines as a partner.
Acacia Research Corp., of Newport Beach, Calif., appointed Matthew Moore director of research and development, Robert Embree director of laboratory operations, and John Besser chief financial officer of CombiMatrix Molecular Diagnostics.
Barrier Therapeutics Inc., of Princeton, N.J., appointed Carol Raphael to its board.
BioMimetic Pharmaceuticals Inc., of Franklin, Tenn., appointed Steven Hirsch executive vice president, orthopedics and chief operating officer; and Earl Douglas general counsel.
Caraco Pharmaceutical Laboratories Ltd., of Detroit, appointed John Crissman and Madhava Reddy to its board.
Celladon Corp., of La Jolla, Calif., appointed Stephen Grant chief medical officer.
Cephalon Inc., of Frazer, Pa., appointed Jeff Myers vice president, government affairs.
Cepheid, of Sunnyvale, Calif., appointed David Persing executive vice president, chief medical and technical officer.
Ceragenix Pharmaceuticals Inc., of Denver, appointed Sean Gorman to its scientific advisory board.
Ceregene Inc., of San Diego, appointed John Walker independent board member.
Chronogen Inc., of Montreal, appointed Jean Davignon, Jean-Charles Fruchart, Marc Prentki, Francesco Violi, and Jean-Claude Tardif to its scientific advisory board.
CompuMed Inc., of Los Angeles, appointed Scott Evers vice president of sales and Henky Wibowo vice president of engineering. It also promoted Xiaoli Bi to chief technology officer.
Cytel Inc., of Cambridge, Mass., appointed John Hallinan chief financial officer.
Cytomedix, of Rockville, Md., appointed Andrew Maslan chief financial officer.
DeCode genetics, of Reykjavik, Iceland, appointed Daniel Hartman senior vice president of product development, and added David Hermann and Peter Van Ess to its drug development team.
DiagnoCure Inc., of Quebec, appointed Timothy Holzer head of the research and development program.
Emergent BioSolutions, of Gaithersburg, Md., appointed Shahzad Malik to its board.
Endocyte Inc., of West Lafayette, Ind., appointed Richard Messman vice president clinical affairs.
Exelixis Inc., of South San Francisco, appointed Ian Malcolm vice president of strategic marketing.
FzioMed Inc., of San Luis Obispo, Calif., appointed John Krelle president and chief operating officer.
Genaera Corp., of Plymouth Meeting, Pa., promoted John Armstrong to president and chief operating officer.
GenomiX Inc., of San Diego, appointed James Rotherham chief financial officer, and Peter Myers vice president of drug discovery.
GenVec Inc., of Gaithersburg, Md., appointed Thomas Davis chief medical officer.
Geron Corp., of Menlo Park, Calif., appointed Charles Homcy to its board.
Gilead Sciences Inc., of Foster City, Calif., appointed John Cogan to its board.
Haemonetics Corp., of Braintree, Mass., appointed Richard Meelia and Ronald Merriman to its board.
Halozyme Therapeutics Inc., of San Diego, appointed Sue Bailey to its scientific advisory board.
Human Genome Sciences Inc., of Rockville, Md., appointed Barry Labinger executive vice president and chief commercial officer.
iCo Therapeutics Inc., of Vancouver, British Columbia, appointed Santa Jeremy Ono chief scientific officer.
Icoria Inc., of Research Triangle Park, N.C., appointed Anna Mae Diehl to its scientific advisory board.
Innate Pharma, of Marseilles, France, appointed Agustin de la Calle to head business development.
Interleukin Genetics Inc., of Waltham, Mass., named John McCabe interim chief accounting officer, and Philip Reilly interim chief operating officer.
Intrac Inc., of New York, and its subsidiary Innovative Drug Delivery Systems, appointed William Peters to its board.
IntraLase Corp., of Irvine, Calif., appointed Jay Holmes to its board, and re-elected Thomas Porter as a board member.
Isolagen Inc., of Exton, Pa., appointed Mark Kahil vice president of investor relations.
Magellan Biosciences, of Chelmsford, Mass., appointed Darren Braccia vice president of business development.